[go: up one dir, main page]

NO20081071L - Makrocykliske inhibitorer av hepatitt C virus - Google Patents

Makrocykliske inhibitorer av hepatitt C virus

Info

Publication number
NO20081071L
NO20081071L NO20081071A NO20081071A NO20081071L NO 20081071 L NO20081071 L NO 20081071L NO 20081071 A NO20081071 A NO 20081071A NO 20081071 A NO20081071 A NO 20081071A NO 20081071 L NO20081071 L NO 20081071L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
inhibitors
macrocyclic inhibitors
formula
Prior art date
Application number
NO20081071A
Other languages
English (en)
Inventor
Herman Augustinus De Kock
Abdellah Tahri
Pierre Jean-Marie Raboisson
Kenneth Alan Simmen
Sandrine Marie Helene Vendeville
Lili Hu
Wim Van De Vreken
David Craig Mcgowan
Dominique Louis Nestor Surleraux
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37036843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081071(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20081071L publication Critical patent/NO20081071L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Inhibitorer av HCV med formel (I). og iV-oksidene, saltene, og de stereokjemiske isomerformene derav, hvori RR, L, n og p er som definert her. Farmasøytiske sammensetninger som inneholder forbindelser (I) og fremgangsmåter for fremstilling av forbindelser (I). Biotilgjengelige kombinasjoner av inhibitorene av HCV med formel (I) med ritonavir er også tilveiebrakt.
NO20081071A 2005-07-29 2008-02-29 Makrocykliske inhibitorer av hepatitt C virus NO20081071L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107067 2005-07-29
EP05107413 2005-08-11
PCT/EP2006/064813 WO2007014919A1 (en) 2005-07-29 2006-07-28 Macrocylic inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
NO20081071L true NO20081071L (no) 2008-04-25

Family

ID=37036843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081071A NO20081071L (no) 2005-07-29 2008-02-29 Makrocykliske inhibitorer av hepatitt C virus

Country Status (27)

Country Link
US (1) US7989471B2 (no)
EP (1) EP1912995B1 (no)
JP (1) JP5426163B2 (no)
KR (1) KR101074673B1 (no)
CN (1) CN101233137B (no)
AP (1) AP2473A (no)
AR (1) AR055104A1 (no)
AT (1) ATE517902T1 (no)
AU (1) AU2006274858B2 (no)
BR (1) BRPI0614670A2 (no)
CA (1) CA2617095C (no)
DK (1) DK1912995T3 (no)
EA (1) EA014646B1 (no)
GT (1) GT200600341A (no)
IL (1) IL188283A (no)
JO (1) JO2768B1 (no)
MX (1) MX2008001395A (no)
MY (1) MY152153A (no)
NO (1) NO20081071L (no)
NZ (1) NZ564541A (no)
PE (1) PE20070221A1 (no)
SG (1) SG163613A1 (no)
SI (1) SI1912995T1 (no)
SV (1) SV2008002639A (no)
TW (1) TWI412534B (no)
UY (1) UY29705A1 (no)
WO (1) WO2007014919A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
RS51243B (sr) 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
AU2007272839B2 (en) 2006-07-13 2012-05-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
KR20090101372A (ko) * 2007-01-08 2009-09-25 페노믹스 코포레이션 매크로시클릭 ｃ형 간염 프로테아제 억제제
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
BRPI0807087A2 (pt) * 2007-02-08 2014-06-10 Tibotec Pharm Ltd Inibidores de hcv macrocíclicos substituídos de pirimidina
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
JP2011503201A (ja) 2007-11-14 2011-01-27 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
JP5490778B2 (ja) 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0922912A8 (pt) 2008-12-10 2018-01-02 Achillion Pharmaceuticals Inc peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2417134B1 (en) * 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN101987825B (zh) * 2009-07-31 2014-04-02 上海开拓者医药发展有限公司 一种2-氨基-3-甲基-4-甲氧基苯乙酮的制备方法
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
PE20140039A1 (es) 2010-12-30 2014-03-01 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN107964006A (zh) * 2012-01-11 2018-04-27 艾伯维公司 用于制备hcv蛋白酶抑制剂的方法
AU2013329514A1 (en) 2012-10-08 2015-04-30 Abbvie Inc. Compounds useful for making HCV protease inhibitors
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20160005334A (ko) 2013-03-14 2016-01-14 아칠리온 파르마세우티칼스 인코포레이티드 소바프레비르 제조 방법
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331643T2 (de) 1992-12-29 2002-10-31 Abbott Laboratories, Abbott Park Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CN1515248A (zh) 1996-04-23 2004-07-28 ��̩��˹ҩ��ɷ����޹�˾ 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
EP0932617B1 (en) 1996-10-18 2002-01-16 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
WO2000056331A1 (en) 1999-03-19 2000-09-28 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7273885B2 (en) 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
RS51243B (sr) 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
BRPI0614242A2 (pt) * 2005-07-29 2011-03-15 Medivir Ab inibidores macrocìclicos do vìrus da hepatite c, combinação e composição farmacêutica compreendendo os mesmos, bem como uso e processo para a preparação dos referidos inibidores
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c

Also Published As

Publication number Publication date
ATE517902T1 (de) 2011-08-15
IL188283A (en) 2016-12-29
UY29705A1 (es) 2007-05-31
EP1912995B1 (en) 2011-07-27
SG163613A1 (en) 2010-08-30
NZ564541A (en) 2010-03-26
SV2008002639A (es) 2008-07-23
JP5426163B2 (ja) 2014-02-26
MY152153A (en) 2014-08-15
CN101233137A (zh) 2008-07-30
AU2006274858A1 (en) 2007-02-08
AP2473A (en) 2012-09-24
CA2617095C (en) 2014-05-13
WO2007014919A1 (en) 2007-02-08
GT200600341A (es) 2007-02-26
SI1912995T1 (sl) 2011-11-30
EA014646B1 (ru) 2010-12-30
PE20070221A1 (es) 2007-04-16
CA2617095A1 (en) 2007-02-08
TW200745165A (en) 2007-12-16
CN101233137B (zh) 2014-05-07
US20100240698A1 (en) 2010-09-23
IL188283A0 (en) 2008-04-13
JO2768B1 (en) 2014-03-15
JP2009502882A (ja) 2009-01-29
KR20080041651A (ko) 2008-05-13
US7989471B2 (en) 2011-08-02
HK1116772A1 (en) 2009-01-02
MX2008001395A (es) 2008-04-16
DK1912995T3 (da) 2011-10-24
BRPI0614670A2 (pt) 2011-04-12
EP1912995A1 (en) 2008-04-23
EA200800484A1 (ru) 2008-06-30
AR055104A1 (es) 2007-08-08
TWI412534B (zh) 2013-10-21
KR101074673B1 (ko) 2011-10-19
AU2006274858B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
NO20081071L (no) Makrocykliske inhibitorer av hepatitt C virus
NO20081073L (no) Makrocykliske inhibitorer av hepatitt C virus
EP1924593B8 (en) Hcv ns3 protease inhibitors
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
WO2006119061A3 (en) Hcv ns3 protease inhibitors
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
WO2008051477A3 (en) Hcv ns3 protease inhibitors
MY164469A (en) Hcv ns3 protease inhibitors
NO20081074L (no) Macrocyclisk inhibitorer av hepatitis C-virus
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
WO2013074386A3 (en) Hcv ns3 protease inhibitors
NO20090628L (no) Pyridizinon derivativater
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2007084435A8 (en) Methods for treating hepatitis c
WO2007120374A3 (en) Anti-arenaviral compounds
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application